0001415889-24-006170.txt : 20240301 0001415889-24-006170.hdr.sgml : 20240301 20240301182617 ACCESSION NUMBER: 0001415889-24-006170 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240228 FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Megna Michael R CENTRAL INDEX KEY: 0001464583 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 24712171 MAIL ADDRESS: STREET 1: 1050 HINGHAM STREET CITY: ROCKLAND STATE: MA ZIP: 02370 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: D0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 BUSINESS PHONE: 7814399100 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 4 1 form4-03012024_110310.xml X0508 4 2024-02-28 0001730430 Kiniksa Pharmaceuticals, Ltd. KNSA 0001464583 Megna Michael R C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM 11 BERMUDA false true false false CHIEF ACCOUNTING OFFICER 1 Class A Common Share 2024-01-15 4 A 0 583 12.35 A 17588 D Class A Common Share 2024-02-28 4 M 0 5126 8.83 A 22714 D Class A Common Share 2024-02-28 4 S 0 5126 21.79 D 17588 D Class A Common Share 2024-03-01 4 M 0 5645 8.83 A 23233 D Class A Common Share 2024-03-01 4 M 0 4014 13.88 A 27247 D Class A Common Share 2024-03-01 4 S 0 9659 21.45 D 17588 D Share Option 8.83 2024-02-28 4 M 0 5126 0 D 2029-09-16 Class A Common Share 5126 5874 D Share Option 8.83 2024-03-01 4 M 0 5645 0 D 2029-09-16 Class A Common Share 5645 229 D Share Option 13.88 2024-03-01 4 M 0 4014 0 D 2028-08-05 Class A Common Share 4014 0 D The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2023 to January 15, 2024. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.56 to $21.90. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.45 to $21.49. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This option is fully vested and exercisable. /s/ Madelyn Zeylikman, Attorney-in-Fact 2024-03-01